Ropeginterferon alfa-2b 250 micrograms/0.5 mL solution for injection in pre-filled pen (Besremi®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2421	As monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.	Not routinely available as not recommended for use in NHS Scotland	18/05/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/ropeginterferon-alfa-2b-besremi-full-smc2421/

Other Decision Specified

Date of ADTC 18/05/2022

Pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2420	In combination with platinum and fluoropyrimidine based chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS≥10.	Available in line with local or regional guidance	20/07/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-full-smc2420/

Other Decision Specified

Date of ADTC 18/05/2022

Mepolizumab 100mg powder for solution for injection (Nucala®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2491	As an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.	Not routinely available as not recommended for use in NHS Scotland	18/05/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/mepolizumab-nucala-scr-nonsub-smc2491/

Other Decision Specified

Date of ADTC 18/05/2022

Filgotinib 100mg and 200mg film-coated tablets (Jyseleca®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2467	For the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.	Available in line with local or regional guidance	15/06/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/filgotinib-jyseleca-uc-abb-smc2467/

Other Decision Specified

Date of ADTC 18/05/2022

Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2429	As monotherapy for the adjuvant treatment of adult patients with completely resected oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.	Available in line with local or regional guidance	20/07/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-full-smc2429/

Other Decision Specified

Date of ADTC 18/05/2022

Venetoclax 10mg, 50mg, 100mg film-coated tablets (Venclyxto®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2427	In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). SMC restriction: in patients without del (17p)/TP53 mutation who are fit to receive fludarabine, cyclophosphamide and rituximab (FCR) chemo-immunotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/08/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/venetoclax-venclyxto-full-smc2427/

Other Decision Specified

Date of ADTC 18/05/2022

Cemiplimab 350 mg concentrate for solution for infusion (Libtayo®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2489	As monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: • locally advanced NSCLC who are not candidates for definitive chemoradiation, or • metastatic NSCLC.	Not routinely available as not recommended for use in NHS Scotland	18/05/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/cemiplimab-libtayo-nonsub-smc2489/

Other Decision Specified

Date of ADTC 18/05/2022

Mepolizumab 100mg powder for solution for injection (Nucala®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2488	As add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.	Not routinely available as not recommended for use in NHS Scotland	18/05/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/mepolizumab-nucala-hs-nonsub-smc2488/

Other Decision Specified

Date of ADTC 18/05/2022

Mepolizumab 100mg powder for solution for injection (Nucala®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2490	As an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA).	Not routinely available as not recommended for use in NHS Scotland	18/05/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/mepolizumab-nucala-egpa-nonsub-smc2490/

Other Decision Specified

Date of ADTC 18/05/2022

Oritavancin 400mg powder for concentrate for solution for infusion (Tenkasi®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2285	Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. SMC restriction: patients with confirmed or suspected methicillin-resistant Staphylococcus aureus (MRSA) infection who are eligible for early discharge. Use should be on the advice of local microbiologists or specialists in infectious disease.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/08/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/oritavancin-tenkasi-resub-smc2285/

Other Decision Specified

Date of ADTC 18/05/2022

Dapagliflozin 10mg film-coated tablets (Forxiga®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2428	In adults for the treatment of chronic kidney disease. SMC restriction: * in patients with an estimated glomerular filtration rate of ≥25 to ≤75 mL/min/1.73m2 at treatment initiation, and * are receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker (unless these are not tolerated or contraindicated), and * have a urine albumin creatinine ratio of at least 23mg/mmol, or type 2 diabetes mellitus or both.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/08/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/dapagliflozin-forxiga-full-smc2428/

Other Decision Specified

Date of ADTC 18/05/2022

Daratumumab concentrate for solution for infusion and solution for injection (Darzalex®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2416	In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Not routinely available as not recommended for use in NHS Scotland	18/05/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/daratumumab-iv-and-sc-darzalex-full-smc2416/

Other Decision Specified

Date of ADTC 18/05/2022

Liraglutide 6mg/mL solution for injection in pre-filled pen (Saxenda®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision

SMC2455	As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of: ≥30kg/m² (obese), or ≥27kg/m² to<30kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. SMC restriction: BMI ≥35kg/m2* (obesity class II and above) with: Non-diabetic hyperglycaemia (prediabetes) at high risk of type 2 diabetes which is defined as having either: fasting plasma glucose level of 5.5 to 6.9mmol/L or HbA1c of 6.0 to 6.4% (42 to 47mmol/mol), and high risk of cardiovascular disease(CVD): total cholesterol >5mmol/L, or high-density lipoprotein (HDL) <1.0mmol/L for men and <1.3mmol/L for women, or systolic blood pressure (SBP) >140mmHg. Patients should be treated in a specialist weight management service. *a lower BMI cut-off may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.	Not routinely available as local implementation plans are being developed - decision expected by	31/08/2022

Web Links https://www.scottishmedicines.org.uk/medicines-advice/liraglutide-saxenda-resub-smc2455/

Other Decision Specified

Date of ADTC 18/05/2022